Redeye: AroCell - Changes to the Case

Report this content

Redeye significantly raises its Base Case for AroCell, given fundamental changes to the case following recent FDA filing in combination with close discussions with management. The company is transitioning to a more commercially oriented business with anticipated key activities in the coming 6-9 months. At a current market capitalization of roughly SEK 130m, we see great upside in the stock on all horizons.

Read more and download the research update

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.